Payal D. Shah, MD, discusses the paradigm shift in metastatic HR-positive, HER2-negative breast cancer, now largely defined by the use of CDK4/6 inhibitors.
Original Article: CDK4/6 Inhibitors Showing Survival Gains in Metastatic HR+ Breast Cancer